Asia Executives On The Move: BeiGene, Henlius, Dainippon Sumitomo
Executive Summary
Another busy time for executive moves in the Asia Pacific region, as Amgen China GM joins Henlius, BeiGene appoints new immuno-oncology CMO and Sumitomo Dainippon names a new digital health head. Changes also take place at Ascentage, Harbin Pharma and AdvaMed.
You may also be interested in...
What Lies Beneath China's Steep Price Cuts For New Drugs
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Asia Executives On The Move: BMS, Pfizer, Takeda, RDPAC
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.
Who's In And Who's Out In China's Largest Reimbursed Drug List Revamp?
Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: